Skip to content
  1. Home/
  2. Latest news/
  3. What you need to know about Johnson & Johnson’s 2022 first-quarter earnings
what-you-need-to-know-about-johnson-and-johnsons-2022-first-quarter-earnings-lede.png

What you need to know about Johnson & Johnson’s 2022 first-quarter earnings

Check out this infographic breakdown of the company’s first-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

q1-2022-quarterlyearnings-0422.png

This morning, Johnson & Johnson shared its first-quarter performance.

Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

“Even in the face of some macro-economic headwinds, Johnson & Johnson posted strong results for the quarter, continuing to deliver reliable growth and investing to advance our pipeline. We’re proud to announce a dividend increase for the 60th consecutive year, a key capital allocation priority. We remain well positioned to accelerate innovation as we evolve into a smarter era of healthcare, and work to successfully stand up the New Consumer Health Company,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson.

For more details about the company’s 2022 first-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


An infographic showing key stats about Johnson & Johnson's first-quarter 2022 earnings

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

Johnson & Johnson named to Fortune’s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.